A 38-year-old male from Delhi with a 10-year history of recurrent gout attacks is now on allopurinol 300 mg daily. His serum uric acid is well controlled at 5.8 mg/dL. However, he presents with acute onset severe pain in both knees and the right elbow, along with fever (38.5°C) and malaise. Laboratory findings show: WBC 12,000/μL, CRP elevated, and uric acid remains at 5.8 mg/dL. Synovial fluid analysis from the knee shows needle-shaped, negatively birefringent crystals. Which of the following best explains the acute polyarticular presentation despite adequate urate control?

Explanation

## Crystal Mobilization Flare During Urate-Lowering Therapy **Key Point:** Paradoxical acute gout flares can occur when serum uric acid is rapidly lowered, even if it remains in the "normal" range. This is due to crystal shedding from tophi and joint deposits as the uric acid concentration drops below the saturation point. ### Mechanism of Mobilization Flare 1. **Crystal Deposition Phase:** Over years, monosodium urate (MSU) crystals accumulate in joints, cartilage, and soft tissues (tophi). 2. **Rapid Urate Lowering:** When ULT (allopurinol, febuxostat) is initiated or escalated, serum uric acid drops rapidly. 3. **Undersaturation:** As serum uric acid falls below the saturation point (~6.8 mg/dL), the gradient favors crystal dissolution and shedding from deposits. 4. **Acute Inflammation:** Shed crystals trigger acute IL-1β–mediated inflammation in joints, causing polyarticular flares. 5. **Self-Limited:** The flare resolves within 7–10 days as the inflammatory cascade completes. **High-Yield:** This phenomenon is called a **"mobilization flare"** or **"urate-lowering flare"** and is a known, expected complication of initiating ULT. It does NOT indicate treatment failure—it is a sign that ULT is working. ### Clinical Features of Mobilization Flare | Feature | Characteristic | |---------|----------------| | **Timing** | Days to weeks after starting or escalating ULT | | **Pattern** | Often polyarticular (multiple joints affected) | | **Serum Uric Acid** | Normal or low (< 6 mg/dL) | | **Synovial Fluid** | Needle-shaped, negatively birefringent MSU crystals | | **Duration** | Self-limited; resolves in 7–10 days | | **Prevention** | Co-prescribe colchicine or NSAIDs for 3–6 months when starting ULT | **Clinical Pearl:** The presence of negatively birefringent needle-shaped crystals in synovial fluid confirms acute gout, regardless of serum uric acid level. The polyarticular presentation and fever are consistent with a severe mobilization flare. ### Why This Patient's Presentation Fits Mobilization Flare - **Well-controlled baseline uric acid (5.8 mg/dL):** Indicates effective ULT. - **Acute polyarticular flare:** Typical of crystal shedding from multiple deposits. - **Negatively birefringent crystals in synovial fluid:** Confirms MSU gout, not another arthropathy. - **Fever and systemic symptoms:** Consistent with acute inflammatory response to crystal shedding. - **No recent ULT change mentioned:** However, the question implies adequate control, suggesting the patient may have been on stable therapy—flares can still occur if deposits are being remodeled. ### Prevention and Management ```mermaid flowchart TD A[Starting ULT]:::action --> B[Co-prescribe prophylaxis]:::action B --> C{Prophylactic agent}:::decision C -->|Preferred| D[Colchicine 0.5 mg daily]:::action C -->|Alternative| E[NSAID for 3-6 months]:::action C -->|If contraindicated| F[Low-dose corticosteroid]:::action D --> G[Continue for 3-6 months]:::action E --> G F --> G G --> H[Reduces mobilization flare risk by 75%]:::outcome ``` **Mnemonic:** **FLARE** = **F**all in urate **L**evels **A**ctivates **R**eleased crystals, **E**xciting inflammation.